Amylyx is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases.

Register for Details

For more details on financing and valuation for Amylyx, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Amylyx's ticker symbol?


What is Amylyx's stock price?

18.88 as of 9/19/23

Amylyx Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
7/20/2021 Series C-1 and C-2 $135MM raised $XXX.XX $XXX.XX
7/1/2020 Series B $60.52MM raised $XXX.XX $XXX.XX
8/23/2016 Series A $7.73MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Amylyx

Forge green plus iconForge green minus icon

What is Amylyx funding to date?

Amylyx has raised $203.25MM to date.
Forge green plus iconForge green minus icon

When was Amylyx founded?

Amylyx was founded in 2014.
Updated on: Jun 12, 2022